Influenza hemagglutinin and neuraminidase variants

Details Influenza hemagglutinin and neuraminidase variants Influenza hemagglutinin and neuraminidase variants

2010-09-07

2011-11-01

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S209100, C435S239000, C435S235100

Reexamination Certificate

active

08048430

ABSTRACT:
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.

REFERENCES:
patent: 3992522 (1976-11-01), Chanock et al.
patent: 4071618 (1978-01-01), Konobe et al.
patent: 4634666 (1987-01-01), Engleman et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5690937 (1997-11-01), Parkin et al.
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5820871 (1998-10-01), Palese et al.
patent: 5840520 (1998-11-01), Clarke et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: 5922326 (1999-07-01), Murphy
patent: 6001634 (1999-12-01), Palese et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6090391 (2000-07-01), Parkin
patent: 6146642 (2000-11-01), Garcia-Sastre et al.
patent: 6146873 (2000-11-01), Kistner et al.
patent: 6168943 (2001-01-01), Rose
patent: 6951754 (2005-10-01), Hoffmann
patent: 7037707 (2006-05-01), Webster et al.
patent: 7459162 (2008-12-01), Yang
patent: 7566458 (2009-07-01), Yang
patent: 2002/0119445 (2002-08-01), Parkin
patent: 2002/0164770 (2002-11-01), Hoffmann
patent: 2003/0035814 (2003-02-01), Kawaoka
patent: 2003/0147916 (2003-08-01), Ferko
patent: 2004/0029251 (2004-02-01), Hoffman et al.
patent: 2004/0071734 (2004-04-01), Garcon et al.
patent: 2004/0137013 (2004-07-01), Katinger
patent: 2005/0042229 (2005-02-01), Yang
patent: 2005/0266026 (2005-12-01), Hoffmann
patent: 2006/0252132 (2006-11-01), Yang et al.
patent: 2007/0253982 (2007-11-01), Song et al.
patent: 2011/0002960 (2011-01-01), Yang
patent: 1536077 (2004-10-01), None
patent: 0702085 (1996-03-01), None
patent: 0863202 (1998-09-01), None
patent: 0864645 (1998-09-01), None
patent: 0780475 (1999-06-01), None
patent: 1826269 (2007-08-01), None
patent: WO 91/03552 (1991-03-01), None
patent: WO 93/21306 (1993-10-01), None
patent: WO 96/10632 (1996-04-01), None
patent: WO 96/34625 (1996-11-01), None
patent: WO 96/37624 (1996-11-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/13501 (1998-04-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15672 (1999-04-01), None
patent: WO 00/53786 (2000-09-01), None
patent: WO 00/60050 (2000-10-01), None
patent: WO 2005/018539 (2005-03-01), None
patent: WO 2006/098901 (2006-09-01), None
patent: WO 2010/006144 (2010-01-01), None
Ellis and Zambon, Molecular analysis of an outbreak of influenza in the United Kingdom, 1997, European Journal of Epidemiology, vol. 13, pp. 369-372.
Chen et al., Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate, 2003, Vaccine, vol. 21, pp. 1974-1979.
Banerjee and Barik, 1992, “Gene expression of vesicular stomatitis virus genome RNA”, Virology. 188(2):417-28.
Baron and Barrett, 1997, “Rescue of Rinderpest Virus from Cloned cDNA”, J. Virol. 71:1265-1271.
Basler et al., Mutation of Neuraminidase Cysteine Residues Yields Temperature-Sensitive Influenza Viruses, Journal of Virology, Oct. 1999, vol. 73, No. 10, p. 8095-8103.
Beare et al., 1975, “Trials in Man with Live Recombinants Made from A/NPR/8/34 (HO N1) and Wild H3 N2 Influenza Viruses”, Lancet 2(7938):729-732.
Belshe, 1995 “A Review of Attenuation of Influenza Viruses by Genetic manipulation,” American Journal of Respiratory and Critical Care Medicine 152[4 Pt 2], 572-575. 1995.
Belshe, et al., “The Efficacy of live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine in children,” N Eng J Med 338:1405-1412, 1998.
Bender et al., 1999, “Characterization of the surface proteins of influenza A (H5NI) viruses . . . ”, Virology 254(1):115-23.
Bergmann, et al., “The relative amount of an influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment,”. Journal of General Virology, 1995,76:3211-3215.
Boyce et al., 2001, “Safety and immunogonicity of adjuvanted and unadjuvanled subunit influenza vaccines administered Intranasally to healthy adults”, Vaccine 19:217-226.
Boyer et al., 1994, “Infectious transcripts and cDNA clones of RNA viruses”, Virology. 198(2):415-26.
Brandt et al., 2001, “Molecular Determinants of Virulence, Cell Tropism. and Pathogenic Phenotype of Infectious Bursal Disease Virus”. Journal of Virology 75(24):11974-11982.
Brigden and Elliott. 1996, “Rescue of a Segmented Negative-Strand RNA Virus Entirely from Cloned Complementary DNAS”, Proc. Natl. Acad. Sci. USA 93:15400-15404.
Buchholz et al., 1999 “Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture. and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter”. J. Virol. 73:251-259.
Bukreyev et al., 1996, “Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene”, J Virol. 70(10):6634-6641.
Castrucci et al., 1995, “Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein”, J Virol. 69(5):2725-2728.
Chen et al., 1999, “Influenza A virus NS1 protein targets poly (A)-binding protein II of the cellular 3′-end processing machinery”, EMBO 18: 2273-2283.
Clarke et al., 2000, “Rescue of mumps virus from cDNAJ”, J Virol. 74(10):4831-8.
Collins et al., 1991, “Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations and Mutations on the Expression of a Foreign Reporter Gene”, Proc. Natl. Acad. Sci. USA 88:9663 9657.
Collins et al., 1995, “Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role . . . ” PNAS 92: 11563-7.
Collins et al., 1996, “Parainfluenza Viruses”, Fields Virology, Lippincott-Raven Publishers, Phila., Chapter 41, pp. 1205-1241.
Conzelmann et al., 1994, “Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins”, J Virol. 68(2):713-9.
Conzelmann et al., 1996, “Genetic engineering of animal RNA viruses”, Trends Microbiol. 4(10):386-93.
Conzelmann et al., 1996, “Genetic manipulation of non-segmented negative-strand RNA viruses”, J Gen Virol. 77 (Pt 3):381-389.
Conzelmann et al., 1998, “Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes”, Annu Rev Genet. 32:123-62.
Cox. NJ et al., “Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain . . . ”. Virology. Dec. 1988; 167(2)554-567.
Database Caplus on NCBI, Accession No. AY553802, Influenza A Virus (A/little grebe/Thailand/Phichit-01/2004(H5N1) hemagglutinin {HA) gene, partial cds. May 21, 2004.
Daum et al., Influenza A (H3N2) Outbreak, Nepal, 2005, Emerging Infectious Diseases, vol. 11, No. 8, pp. 1186-1191.
De and Banerjee, 1985, “Requirements and Functions of Vesicular Stomatitis Virus Land NS Proteins in the Transcription Process in vitro”, Biochem. Biophys. Res. Commun. 126:40-49.
De and Banerjee, 1993, “Rescue of synthetic analogs of genome RNA of human parainfluenza virus type 3”, Virology, 96(1 ):344-8.
De and Banerjee, 1994, “Reverse genetics of negative strand RNA viruses”, Indian J Biochem Biophys. 31(5):367-76.
De et al., “Complete sequence ofa cDNA clone of the hemagglutinin gene of influenza A/Chicken/Scotland/59 (H5NI) virus: comparison with contemporary North American and European strains,” Nucleic Acids Research, 1988. vol. 16, No. 9, pp. 4181-4182.
De et al., “Protection against virulent H5 avian influenza virus infection in chickens by an inactivated vaccine produced with recombinant vaccine virus”, Jun. 1988

Affiliated with

Also associated with

Rating

Influenza hemagglutinin and neuraminidase variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza hemagglutinin and neuraminidase variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza hemagglutinin and neuraminidase variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4272866